Clinical Data on AZP-3601 for Hypoparathyroidism Presented at ENDO 2021
rawpixel / Pixabay

Clinical Data on AZP-3601 for Hypoparathyroidism Presented at ENDO 2021

  At the Endocrine Society's Annual Meeting, or ENDO 2021, Amolyt Pharma ("Amolyt") shared positive clinical data from a Phase 1 clinical trial evaluating AZP-3601 for patients with hypoparathyroidism. Although…

Continue Reading Clinical Data on AZP-3601 for Hypoparathyroidism Presented at ENDO 2021
First Patient Dosed in Trial of Hypoparathyroidism Treatment, AZP-3601
DarkoStojanovic / Pixabay

First Patient Dosed in Trial of Hypoparathyroidism Treatment, AZP-3601

Amolyt Pharma has recently announced that they have dosed the first patient in their trial of AZP-3601, a treatment for hypoparathyroidism. According to GlobeNewswire, this treatment will adequately address the…

Continue Reading First Patient Dosed in Trial of Hypoparathyroidism Treatment, AZP-3601
International Phase 2 Clinical Trial Initiated for New Potential Hypoparathyroidism Therapy
Source: Pixabay

International Phase 2 Clinical Trial Initiated for New Potential Hypoparathyroidism Therapy

Hypoparathyroidism Hypoparathyroidism (HP) is caused by low levels of the parathyroid hormone (PTH). Most people develop this disease after thyroid surgery as a result of accidental damage/removal of the parathyroid…

Continue Reading International Phase 2 Clinical Trial Initiated for New Potential Hypoparathyroidism Therapy